Shopping Cart
Remove All
Your shopping cart is currently empty
CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $129 | - | In Stock | |
| 10 mg | $198 | - | In Stock | |
| 25 mg | $455 | - | In Stock | |
| 50 mg | $787 | - | In Stock | |
| 100 mg | $1,280 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $143 | - | In Stock |
| Description | CGP 53353 (DAPH-7) is a PKC inhibitor with inhibitory effects on PKCβII and PKCβI and can be used to study atherosclerosis. |
| Targets&IC50 | PKCβI:3.8 mM, PKCβII:0.41 mM |
| In vitro | In A10 cells, CGP-53353 (DAPH-7) inhibits glucose-induced cell proliferation when administered at 1 μM for 48-96 hours[1]. At a concentration of 1 μM for the initial 0-48 hours, CGP-53353 inhibits the glucose-induced increase and acceleration of DNA synthesis in A10 cells. It also blocks the glucose-induced increase in the percentage of S-phase cells[1]. |
| Synonyms | DAPH-7 |
| Molecular Weight | 365.33 |
| Formula | C20H13F2N3O2 |
| Cas No. | 145915-60-2 |
| Smiles | Fc1ccc(Nc2cc3C(=O)NC(=O)c3cc2Nc2ccc(F)cc2)cc1 |
| Relative Density. | 1.31g/cm3 |
| Color | Orange |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: < 7.31 mg/mL, Sonication is recommended. DMSO: 50 mg/mL (136.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.